NexCAR19™ is a prescription drug for treating specific relapsed or refractory B-cell Non-Hodgkin’s Lymphomas and B-cell Acute Lymphoblastic Leukaemia when frontline therapy or other standard treatments have been unsuccessful.
NexCAR19™
A New Hope for Hard to Treat B-Cell Cancers
Talk to Our Care Team
Patients
HCP
What is NexCAR19™ ?
Is NexCAR19™ for you?
If you’re 15 or older and have B-cell Non-Hodgkin’s Lymphoma or B-cell Acute Lymphoblastic Leukaemia, your haematologist or medical oncologist might recommend NexCAR19™ if:
- Frontline treatment was not sufficient to achieve complete remission.
- Previous treatment didn’t work, or the cancer returned after remission.
- Stem cell transplant failed or is not suitable
Which cancers can NexCAR19™ treat?
NexCAR19™ is for patients with challenging B-cell cancers, which are often inadequate to treat with chemoimmunotherapy.
Diffuse Large B-cell Lymphoma (DLBCL)
Most common aggressive B-cell lymphoma type.
Primary Mediastinal B-cell Lymphoma (PMBCL)
A rare chest-based lymphoma in younger adults.
Follicular Lymphoma (FL)
Slow-growing with potential to transform aggressively.
Mantle Cell Lymphoma (MCL)
Rare subtype often diagnosed late and challenging.
Marginal Zone Lymphoma (MZL)
Associated with inflammation or infection origins.
High-Grade B-cell Lymphoma
Rapid progression, requires fast-acting therapies.
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Aggressive leukemia impacting bone marrow and blood.
Why NexCAR19™ ?
Total Patients Treated
350+
Lives transformed through treatment
B-NHL Response Rate
72%
at 30 days in clinical trials
B-ALL Response Rate
73%
at 30 days in clinical trials
Survival Chances at 1 year
> 50%
in unmet B-NHL & B-ALL in clinical trials
Vein-To-Vein Time
~20 days
in Clinical Trials
Longest Remission
2+ Years
of sustained response
Low Hospitalization Duration
<15 days
post infusion, barring severe side effects
Last updated April 2025
Real Stories of Hope
How does NexCAR19™ work?
NexCAR19™ is a type of CAR-T cell therapy. T-cells are naturally made by your body as an advanced defense against viruses and cancer cells. As they mature, they develop specific connectors (receptors) to target key signals in cancer cells. However, cancers can escape the inbuilt defense mechanism of T-cells, which can lead to an increase in tumor burden and can result in the survival of cancer cells and a further increase in tumor burden. CD19 is a protein commonly present on the surfaces of certain B-cell cancers.
Our scientists have designed instructions for your T-cells to express unique proteins called Chimeric Antigen Receptors (CARs) on their surface, which will enable them to bind to a specific target on the cancer cells. These instructions are delivered genetically using a vehicle known as a lentiviral vector.NexCAR19 targets a marker called CD19, which is commonly present on the surface of cancerous B-cells.
1. Isolate
Select and activate T-cells from the patient’s blood sample.
2. Program
Deliver genetic instructions to T-cells using viral vectors.
3. Engineer
Enable T-cells to express Chimeric Antigen Receptors (CARs).
4. Expand
Multiply CAR-T cells to achieve the therapeutic dose.
5. Infuse
Administer CAR-T cells to the patient for targeted cancer treatment.
Treatment Process
A comprehensive guide through each step of your NexCAR19 treatment journey, detailing what to expect and how to prepare ?
Partnered Hospitals
Our strong association with over 80 leading cancer treatment hospitals in India ensures hassle-free treatment with our CAR-T cell therapies.
During Treatment
During Treatment
Planning & Considerations
Navigating your journey with strength and support
Treatment plan
Your treatment team will schedule a process for collecting white blood cells (leukapheresis), based on:
Disease burden: If it’s high, your doctor may plan NexCAR19 treatment alongside another therapy to reduce it first.
Timing of prior treatments: Since NexCAR19™ uses your T-cells, previous immunotherapies or chemotherapies might impact their quality or quantity. Your doctor will time the collection and treatment to ensure the best T-cells are available to fight your cancer.
Considerations
The cell collection process happens at the treatment center.
It is a day-care procedure, and usually requires 4-6 hours.
It is recommended to wear loose-fitting clothing for the procedure.
ImmunoACT processes the Leukapheresis sample within 24 hours. The hospital will inform you when manufacturing is proceeding.
Treatment Process
Your Journey to Recovery
A Step-by-Step Path Through CAR-T Cell Therapy
Step 01
Consultation
At the certified treatment center, you will meet with your team and get assessed to see if you are eligible for NexCAR19.
Step 02
Collecting your blood cells
White blood cells are collected through apheresis, a process similar to blood donation.
Step 03
Making NexCAR19™
After collecting your blood cells, NexCAR19™ is usually manufactured around 15 days.
Step 04
Bridging Therapy
In the Interim period, your physician may administer a Bridging Therapy to lower your disease burden.
Step 05
Conditioning Chemotherapy
~5 days before NexCAR19™’s infusion, you will start receiving a Conditioning Chemotherapy so that your body is ready for NexCAR19™’s infusion.
What are the Side Effects of NexCAR19?
NexCAR19™ may cause side effects that are severe and/or life-threatening. Call/visit your physician or get emergency help right away if you get any of the following
Fever (100.4°F/38°C or higher)
Difficulty breathing
Chills or shaking chills
Confusion
Dizziness or lightheadedness
Severe nausea, vomiting, or diarrhea
Fast or irregular heartbeat
Severe fatigue or weakness
Precautions
Before receiving NexCAR19™, inform your physician about any medical issues, including if you have or have had
-
Neurologic problems (such as seizures, stroke, or memory loss).
-
Lung or breathing problems.
-
Heart problems.
-
Liver problems.
-
Kidney problems.
-
A recent or active infection.
Inform your physician about all the medications you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Inform your physician if you are pregnant, planning to be pregnant, or breastfeeding.
A pregnancy test may be then performed prior to your starting treatment. No information is available of NexCAR19 use in pregnant or breastfeeding women, hence, its use is not recommended in cases of pregnancy.
For Caregivers
What is my role as a caregiver?
Caregivers play a vital role in CAR T treatment, providing essential support throughout the patient’s recovery. CAR T patients require a full-time caregiver to:
- Stay with them for at least 4 weeks near a certified healthcare facility, as advised by the treatment team.
- Monitor for side effects, including those the patient may not notice (refer to “Managing Side Effects” and “Important Facts about ImmunoACT” for details).
- Assist with daily activities and recovery, such as maintaining a healthy diet and clean surroundings.
- Provide transportation, as patients should not drive for at least 8 weeks post-infusion.
How do you prepare for the journey?
Your loved one’s journey with B-cell cancer is filled with challenges. Being prepared for each step of this treatment will smoothen the care process.
- Insurance paperwork & cards
- Medical records including laboratory tests, chemotherapy reports, CT scans or bone marrow biopsy reports
- List & duration of prior treatments, and responses to each of the treatments
- List of current medications.
NexCAR19™ Patient Information Guide
Essential information guide for NexCAR19™ (Acetalycabtagene autoleucel), a CAR-T cell therapy for treating relapsed/refractory B-cell lymphomas and B-cell acute lymphoblastic leukemia.
